Companion Medical Announces FDA Clearance for the InPen System for Android

Companion Medical, a leader in the development of advanced technology to improve diabetes care, has received FDA clearance for the Android version of its InPen app, clearing the way for release of the first smart pen system for Android users. The InPen system has been commercially available for iOS users since December 2017 and is the only FDA-cleared, smart insulin pen paired with an integrated diabetes management app. “We are excited to make the InPen system available for Android devices so that we can bring the latest in connected diabetes technology to Android users,” said Companion’s Chief Executive Officer Sean Saint. “Our mission is to empower people living with diabetes and their healthcare providers with easy-to-use connected solutions that improve outcomes at a lower cost. With diabetes, it is about taking the right amount of insulin at the right time. InPen’s dose calculator, insulin-on-board tracking, and dose reminders do all the tracking, monitoring, and complex calculations for users, while also providing healthcare professionals with the data they need.”

Upon release of the Android app, expected by the fourth quarter of this year, a new group of people living with diabetes will be able to rely on InPen to automatically calculate insulin doses, receive dose reminders, and send reports from their phones directly to their caregivers. The Insights by InPen report displays aggregated glucose, insulin, and meal data with detailed daily views, which enables providers to monitor glucose control and adherence patterns, identify the cause and effect of key decisions, and make targeted improvements to therapy. InPen is available in the US by prescription only. The app is available for download on the Apple App Store and will be available later this year in the Android marketplace. – Medical Buyer Bureau